Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177-CDCP1 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Shandong Cancer Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lutetium Lu 177-CDCP1 monoclonal antibody is a CDCP1-targeted therapeutic radiopharmaceutical under preclinical development for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). It consists of a recombinant human monoclonal antibody targeting CUB domain-containing protein 1 (CDCP1) conjugated to the chelator p-SCN-Bn-DOTA and radiolabeled with the beta-emitting radionuclide lutetium-177 (177Lu). CDCP1 is a cell-surface receptor that is overexpressed in various cancers and is associated with radiotherapy resistance. By binding specifically to CDCP1 on tumor cells, the radioconjugate delivers localized beta radiation, inducing DNA damage and tumor cell death. In preclinical models of radioresistant NSCLC, the agent has demonstrated potent antitumor activity both as a monotherapy and in combination with external beam radiotherapy.
- Other names
- 177Lu-CDCP1 mAb177Lu-labeled CDCP1 monoclonal antibody[177Lu]Lu-CDCP1 mAblutetium Lu 177-CDCP1 mAb
02
Targets
CDCP1 (CUB domain-containing protein 1)
Beyond the preview
Go deeper on lutetium Lu 177-CDCP1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177-CDCP1 monoclonal antibody.